Separation at source still lagging

"THINGS have improved, but there is still a long way to go." Read full story ...

Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...